Fexofenadine是第三代抗组胺药,用于治疗过敏症状,如花粉热,鼻塞和荨麻疹,抑制H1受体IC50值为246 nM。
Fexofenadine inhibits histamine H1 receptor with IC50 of 246 nM.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Pratt, C.M., et al. 1999. Am. J. Cardiol. 83: 1451-1454. PMID: 10335761
[2] Juergens, U.R., et al. 2006. Pharmacology. 78: 129-135. PMID: 17016062
[3] Gillard, M. and Chatelain, P. 2006. Eur. J. Pharmacol. 530: 205-214. PMID: 16388798
分子式 C32H39NO4.HCl |
分子量 538.12 |
CAS号 153439-40-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 100 mg/mL |
Water 1 mg/mL |
Ethanol 100 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01133483 | Healthy | Drug: Fexofenadine HCl + Pseudoephedrine HCl | Dr. Reddy's Laboratories Limited | Phase 1 | 2007-04-01 | 2010-06-11 |
NCT01133470 | Healthy | Drug: Fexofenadine HCl + Pseudoephedrine HCl | Dr. Reddy's Laboratories Limited | Phase 1 | 2007-02-01 | 2010-06-11 |
NCT00637455 | Seasonal Allergic Rhinitis | Drug: fexofenadine HCl | Sanofi | Phase 4 | 2003-09-01 | 2011-01-10 |
NCT00637611 | Seasonal Allergic Rhinitis | Drug: Fexofenadine HCl | Sanofi | Phase 4 | 2003-02-01 | 2011-01-11 |
NCT00637884 | Cat Induced Allergic Rhinitis | Drug: Fexofenadine HCl | Sanofi | Phase 4 | 2003-11-01 | 2011-01-10 |
NCT01066754 | Healthy | Drug: Fexofenadine | Dr. Reddy's Laboratories Limited | Phase 1 | 2002-04-01 | 2010-02-09 |
NCT01066767 | Healthy | Drug: Fexofenadine | Dr. Reddy's Laboratories Limited | Phase 1 | 2002-04-01 | 2010-02-09 |
NCT00638118 | Allergic Rhinitis | Drug: Fexofenadine | Sanofi | Phase 4 | 2003-02-01 | 2011-01-10 |
NCT00637585 | Allergic Rhinitis | Drug: Fexofenadine | Sanofi | Phase 4 | 2002-12-01 | 2011-01-10 |
NCT01888718 | Healthy | Drug: Fexofenadine Hydrochloride | Dr. Reddy's Laboratories Limited | Phase 1 | 2011-02-01 | 2013-06-26 |
NCT02908750 | Non Small Cell Lung Cancer | Drug: Fexofenadine tablet dosing|Drug: Osimertininb tablet dosing | AstraZeneca|Quintiles, Inc. | Phase 1 | 2017-01-01 | 2016-09-23 |
NCT01767272 | Healthy | Drug: fexofenadine | Damanhour University | 2012-12-01 | 2013-01-10 | |
NCT00794768 | Seasonal Allergic Rhinitis | Drug: desloratadine 5 mg|Drug: fexofenadine | Merck Sharp & Dohme Corp. | Phase 4 | 2002-11-01 | 2015-06-19 |
NCT00794248 | Seasonal Allergic Rhinitis | Drug: desloratadine 5 mg|Drug: fexofenadine | Merck Sharp & Dohme Corp. | Phase 4 | 2002-11-01 | 2015-04-01 |
NCT00783133 | Seasonal Allergic Rhinitis | Drug: Desloratadine 5 mg|Drug: fexofenadine | Merck Sharp & Dohme Corp. | Phase 4 | 2002-11-01 | 2017-03-21 |
NCT01306721 | Rhinitis Seasonal | Drug: fexofenadine HCL (M016455)|Drug: pseudoephedrine|Drug: fexofenadine HCL matching placebo|Drug: pseudoephedrine matching placebo | Sanofi | Phase 3 | 2011-02-01 | 2013-10-12 |
NCT03078777 | Hemodialysis | Drug: Fexofenadine | Lawson Health Research Institute | Phase 4 | 2017-05-01 | 2017-03-07 |
NCT02157558 | Drug Interactions | Drug: Fexofenadine|Drug: Telotristat etiprate | Lexicon Pharmaceuticals | Phase 1 | 2014-07-01 | 2014-09-05 |
NCT01586091 | Allergic Rhinitis | Drug: Levocetirizine|Drug: Fexofenadine | Charite University, Berlin, Germany | Phase 1 | 2011-02-01 | 2012-04-24 |
NCT00741897 | Rhinitis, Allergic, Perennial | Drug: Fexofenadine | Sanofi | Phase 4 | 2002-03-01 | 2009-09-14 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们